SVRA

SVRA

USD

Savara Inc. Common Stock

$4.130-0.110 (-2.594%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$4.240

最高价

$4.300

最低价

$4.115

成交量

0.81M

公司基本面

市值

831.4M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

1.53M

交易所

NMS

货币

USD

52周价格范围

最低价 $1.89当前价 $4.130最高价 $4.505

相关新闻

PR Newswire

Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz announces that investors with losses related to Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA) have...

查看更多
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GlobeNewswire

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Savara To Contact Him Directly To Discuss Their Options If you suffered losses

查看更多
SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
PR Newswire

Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA

The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the...

查看更多
Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA
PR Newswire

SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May...

查看更多
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
BusinessWire

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of

查看更多
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
PR Newswire

Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRA

Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS...

GlobeNewswire

Savara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SVRA

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ:SVRA). Shareholders who purchased shares of SVRA during the class period listed are